Endocrine
Short-Term BRAF Inhibition with Dabrafenib induced redifferentiation in a subset of patients with BRAF V600E-Mutant papillary thyroid carcinoma.
Fabián Pitoia, Fernando Jerkovich, Martina Rodrigo, Nahiara Woniatczuk, Erika Abelleira
Published: 202510.1007/s12020-025-04518-y
No abstract available for this study.